Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives $40.58 Average PT from Brokerages

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has received an average rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $40.5833.

A number of equities research analysts have recently weighed in on the company. Wells Fargo & Company began coverage on Genmab A/S in a research note on Monday, March 2nd. They set an “overweight” rating and a $40.00 price target on the stock. HC Wainwright increased their price objective on shares of Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Morgan Stanley started coverage on shares of Genmab A/S in a research note on Monday, February 16th. They issued an “equal weight” rating and a $34.00 target price for the company. Guggenheim dropped their target price on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, February 23rd. Finally, Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th.

Genmab A/S Stock Performance

Shares of GMAB opened at $25.73 on Friday. The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86. The firm has a market cap of $16.53 billion, a PE ratio of 16.60, a P/E/G ratio of 1.06 and a beta of 0.94. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $35.43. The stock has a fifty day moving average price of $30.38 and a 200-day moving average price of $30.49.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.41). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Equities research analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Hedge funds have recently made changes to their positions in the company. Vise Technologies Inc. acquired a new stake in Genmab A/S during the 2nd quarter worth about $299,000. Creative Planning increased its holdings in shares of Genmab A/S by 11.8% in the second quarter. Creative Planning now owns 65,132 shares of the company’s stock valued at $1,346,000 after purchasing an additional 6,870 shares during the period. Rockefeller Capital Management L.P. purchased a new position in shares of Genmab A/S in the second quarter worth about $267,000. JPMorgan Chase & Co. raised its stake in shares of Genmab A/S by 17.0% in the second quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock worth $19,282,000 after purchasing an additional 135,814 shares during the last quarter. Finally, Brandywine Global Investment Management LLC lifted its holdings in shares of Genmab A/S by 1.6% during the second quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock worth $36,047,000 after purchasing an additional 27,372 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.